Amarin (AMRN) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Amarin (AMRN) over the past year, gaining 75.5% versus a loss of 37.8%. Over five years, SLGL leads with a -22.8% price change compared with -88.4% for AMRN. Amarin is the larger company by market cap ($253.3 million vs $230.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | SLGL |
|---|---|---|
| Share price | $11.99 | $70.34 |
| Market cap | $253.26M | $230.29M |
| 1-day change | -0.25% | -2.23% |
| YTD return | -14.11% | +70.73% |
| 1-year return | -37.81% | +75.52% |
| 5-year return | -88.38% | -22.85% |
| Forward P/E | 12.23 | — |
| EPS (TTM) | $-1.20 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $97.97 |
| 52-week low | $11.83 | $28.81 |
| Distance from 52-week high | -42.63% | -28.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +4.25% | +116.80% |
| Average volume | 66.16K | 55.30K |
| Shares outstanding | 21.12M | 3.27M |
| Employees | 80 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed AMRN by 113.3 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
AMRN vs SLGL FAQ
Which is bigger, Amarin or Sol-Gel Technologies?
Amarin (AMRN) is larger, with a market capitalization of $253.26M compared with $230.29M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, AMRN or SLGL?
SLGL returned +75.52% over the past 12 months, compared with -37.81% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.